Stock Track | Zevra Therapeutics Plummets 7.75% Following Q3 Revenue Miss and OLPRUVA Sales Cutback

Stock Track11-06

Zevra Therapeutics (ZVRA) saw its stock price plummet by 7.75% during Thursday's trading session, following a disappointing third-quarter earnings report and strategic changes announced by the company. The significant drop surpassed the initial 5.76% decline observed in pre-market trading, indicating heightened investor concerns as the day progressed.

The biopharmaceutical firm reported quarterly revenue of $26.06 million, representing a substantial 605.4% increase year-over-year. However, this figure fell short of the average analyst expectation of $26.63 million. The company's flagship product, MIPLYFFA, for the treatment of Niemann-Pick disease type C, contributed $22.4 million to the total revenue. Despite posting a narrower-than-expected loss of 1 cent per share, beating the consensus estimate of a 4-cent loss, investors seemed to focus more on the revenue miss.

Adding to the negative sentiment, Zevra announced it would be scaling back sales efforts for OLPRUVA due to limited market access. This strategic decision, coupled with the revenue shortfall, appears to have intensified investor concerns about the company's growth prospects, leading to the sharp decline in stock price. The market's reaction underscores the challenges faced by biopharmaceutical companies in meeting both financial expectations and navigating complex market dynamics for their products.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1171540869?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-06 23:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1171540869","market":"sg","top_or_hot":-1,"title":"Stock Track | Zevra Therapeutics Plummets 7.75% Following Q3 Revenue Miss and OLPRUVA Sales Cutback","media":"Stock Track","content":"<p>Zevra Therapeutics (ZVRA) saw its stock price plummet by 7.75% during Thursday's trading session, following a disappointing third-quarter earnings report and strategic changes announced by the company. The significant drop surpassed the initial 5.76% decline observed in pre-market trading, indicating heightened investor concerns as the day progressed.</p>\n\n<p>The biopharmaceutical firm reported quarterly revenue of $26.06 million, representing a substantial 605.4% increase year-over-year. However, this figure fell short of the average analyst expectation of $26.63 million. The company's flagship product, MIPLYFFA, for the treatment of Niemann-Pick disease type C, contributed $22.4 million to the total revenue. Despite posting a narrower-than-expected loss of 1 cent per share, beating the consensus estimate of a 4-cent loss, investors seemed to focus more on the revenue miss.</p>\n\n<p>Adding to the negative sentiment, Zevra announced it would be scaling back sales efforts for OLPRUVA due to limited market access. This strategic decision, coupled with the revenue shortfall, appears to have intensified investor concerns about the company's growth prospects, leading to the sharp decline in stock price. The market's reaction underscores the challenges faced by biopharmaceutical companies in meeting both financial expectations and navigating complex market dynamics for their products.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Zevra Therapeutics Plummets 7.75% Following Q3 Revenue Miss and OLPRUVA Sales Cutback</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Zevra Therapeutics Plummets 7.75% Following Q3 Revenue Miss and OLPRUVA Sales Cutback\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-06 23:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Zevra Therapeutics (ZVRA) saw its stock price plummet by 7.75% during Thursday's trading session, following a disappointing third-quarter earnings report and strategic changes announced by the company. The significant drop surpassed the initial 5.76% decline observed in pre-market trading, indicating heightened investor concerns as the day progressed.</p>\n\n<p>The biopharmaceutical firm reported quarterly revenue of $26.06 million, representing a substantial 605.4% increase year-over-year. However, this figure fell short of the average analyst expectation of $26.63 million. The company's flagship product, MIPLYFFA, for the treatment of Niemann-Pick disease type C, contributed $22.4 million to the total revenue. Despite posting a narrower-than-expected loss of 1 cent per share, beating the consensus estimate of a 4-cent loss, investors seemed to focus more on the revenue miss.</p>\n\n<p>Adding to the negative sentiment, Zevra announced it would be scaling back sales efforts for OLPRUVA due to limited market access. This strategic decision, coupled with the revenue shortfall, appears to have intensified investor concerns about the company's growth prospects, leading to the sharp decline in stock price. The market's reaction underscores the challenges faced by biopharmaceutical companies in meeting both financial expectations and navigating complex market dynamics for their products.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ZVRA","symbol_name":"Zevra Therapeutics","start_time":0,"source_url":"","article_id":"1171540869","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1171540869","pubTimestamp":1762441559,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Zevra Therapeutics (ZVRA) saw its stock price plummet by 7.75% during Thursday's trading session, following a disappointing third-quarter earnings report and strategic changes announced by the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ZVRA":"Zevra Therapeutics"},"translate_title":"股票追踪|Zevra Therapeutics在第三季度营收未达预期和OLPRUVA销售削减后暴跌7.75%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ZVRA":1},"content_text":"Zevra Therapeutics (ZVRA) saw its stock price plummet by 7.75% during Thursday's trading session, following a disappointing third-quarter earnings report and strategic changes announced by the company. The significant drop surpassed the initial 5.76% decline observed in pre-market trading, indicating heightened investor concerns as the day progressed.\nThe biopharmaceutical firm reported quarterly revenue of $26.06 million, representing a substantial 605.4% increase year-over-year. However, this figure fell short of the average analyst expectation of $26.63 million. The company's flagship product, MIPLYFFA, for the treatment of Niemann-Pick disease type C, contributed $22.4 million to the total revenue. Despite posting a narrower-than-expected loss of 1 cent per share, beating the consensus estimate of a 4-cent loss, investors seemed to focus more on the revenue miss.\nAdding to the negative sentiment, Zevra announced it would be scaling back sales efforts for OLPRUVA due to limited market access. This strategic decision, coupled with the revenue shortfall, appears to have intensified investor concerns about the company's growth prospects, leading to the sharp decline in stock price. The market's reaction underscores the challenges faced by biopharmaceutical companies in meeting both financial expectations and navigating complex market dynamics for their products.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1171540869","isCrawlerRequest":true}